News
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demeetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted integration, transposases and the collaboration models speeding biologics from sequence to GMP.
FEATURED STORIES
Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.
Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune.
Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
BioSpace is marking Martin Luther King, Jr. Day by sharing some of our recent coverage about what the life sciences industry is doing to address racial inequality.
The approval of Cibinqo was based on data from five clinical trials of more than 1,600 people. Safety and efficacy were studied in three Phase III trials.
Martin Shkreli and his former company, Vyera Pharmaceuticals, earned a 5,000% increase on the toxoplasmosis drug, Daraprim.
As the COVID-19 pandemic moves into its third year, at least some people think we might be seeing the light at the end of the tunnel as the disease progresses from a pandemic to an endemic stage.
GlaxoSmithKline has declined all three of Unilever PLC’s offers to acquire its Consumer Healthcare business, saying that the proposal undervalued the division’s present and further worth.
Unlike antibody-drug conjugates (ADCs) that focus on antigens, PDCs are able to target the tumor microenvironment that has universal features across solid tumors.
To alleviate the problem of antibiotic-resistant bacteria, or superbugs, several biotechnology companies are developing different strategies to target and kill these microorganisms.
Aria Pharmaceuticals is using a unique computational approach to drug development that has increased its success rate by 30-fold when compared to traditional approaches.
Researchers from UCLA believe they may have a possible new approach to treating, and potentially eradicating HIV.
Beatrice Mintz, the research legend passed away at the age of 100. Her contribution to the field is unforgettable. ere’s more about her and the research.